Yoğun Bakımda COVID-19 Hastalarında Sedasyon ve Analjezi
Özet
Yoğun bakımda tedavi edilen COVID-19 hastalarında noninvaziv ve invaziv mekanik ventilasyon destek ihtiyacı nedeniyle sedasyon ve analjezi uygulamaları hayati bir önem taşımaktadır. COVID-19 hastalarında görülen yüksek solunum iş yükü, belirgin inflamatuar yanıt ve hipermetabolik durum gibi faktörler, bu hastaların COVID-19 dışı yoğun bakım hastalarına kıyasla daha yüksek dozlarda sedatif ve analjezik ajanlara ihtiyaç duymasına yol açmaktadır. Bu süreçte hastaların uyumunu artırmak, solunum eforunu dengelemek ve ventilatör ilişkili akciğer hasarını önlemek amacıyla propofol, deksmedetomidin, midazolam, ketamin ve fentanil gibi ajanlar sıklıkla tek başlarına ya da kombine edilerek yüksek dozlarda kullanılmaktadır. Doğru sedasyon seviyesinin sağlanması için Ramsay Sedasyon Skalası, Richmond Ajitasyon-Sedasyon Skalası (RASS) ve Bispektral İndeks (BİS) gibi subjektif ve objektif izlem yöntemlerinden yararlanılmaktadır. Ancak, uzun süreli ve yüksek dozda uygulanan bu tedavilerin aniden kesilmesi veya hızlıca azaltılması, hastalarda adrenerjik aktivasyon, ajitasyon ve halüsinasyon gibi belirtilerle seyreden ilaç çekilme sendromunu tetikleyebilir. Bu riski en aza indirmek için sedasyon dozlarının kademeli olarak düşürülmesi ve hastaya özel kişiselleştirilmiş tedavi protokollerinin uygulanması en akılcı yaklaşım olarak kabul edilmektedir.
In critically ill COVID-19 patients treated in the intensive care unit, sedation and analgesia applications carry vital importance due to the frequent need for noninvasive and invasive mechanical ventilation support. Factors such as increased work of breathing, exaggerated inflammatory response, and hypermetabolic state observed in COVID-19 patients cause these individuals to require significantly higher doses of sedative and analgesic agents compared to non-COVID-19 intensive care patients. To optimize patient compliance, balance respiratory effort, and prevent ventilator-induced lung injury, agents like propofol, dexmedetomidine, midazolam, ketamine, and fentanyl are frequently utilized at high doses, either alone or in combination. Subjective and objective monitoring methods, including the Ramsay Sedation Scale, Richmond Agitation-Sedation Scale (RASS), and Bispectral Index (BIS), are employed to maintain the correct level of sedation. However, abrupt discontinuation or rapid reduction of these prolonged, high-dose treatments can trigger drug withdrawal syndrome characterized by adrenergic activation, agitation, and hallucinations. To minimize this risk, gradual tapering of sedation doses and implementing personalized, patient-specific treatment protocols are recognized as the most rational therapeutic approaches.
Referanslar
Park G, Sladen RN. Sedation and analgesia in critically ill. 1 st ed. Blackwell Science. Oxford: New Horizons;1995. p.3–60
Sarıcaoğlu F, Akıncı SB, Dal D, Aypar Ü. Yoğun Bakım Hastalarında Analjezi ve Sedasyon. Hacettepe Tıp Dergisi. 2005; 36: 86-90
Kumar A, B. T. Intravenous midazolam for the treatment of refractory status epilepticus. Crit Care Med , 1992; 20: 483-48
Shalansky SJ, Naumann TL, Englander FA: Therapy update: effect of flumazenil on benzodiazepine-induced respiratory depression. Clin Pharm. 1993;12:483–487.
M. Akçabay, Yoğun Bakım Ünitesinde Sedasyon Ağrı Kontrolü ve Paralitik İlaç Kullanımı. Yoğun Bakım Dergisi 2002;2(3):151-161
Nordt SP, Clark RF. Midazolam: a review of therapeutic uses and toxicity. J Emerg Med. 1997;15(3):357-65.
Fragen RJ. Pharmacokinetics and pharmacodynamics of midazolam given viacontinuous intravenous infusion in intensive care units. Clin Ther 1997;19(3):367-8.
JG R. and G. PSA, Clinical Anaesthesia. Nonbarbiturate Intravenous Anesthetics, ed. M. RD. 1994, USA. 247-89.
Smith I, White PF, Nathanson M and Gouldson R: Propofol: An update on its clinical use. Anesthesiology.1994; 81:1005-43.
Southorn PA, Powis G. Free radicals. in medicine I, chemical nature and biologic reactions. Mayo Clinic Proc. 1988; 63:381-89.
Morgan GE, Mikhail MS, Murray MJ, Larson CP. Propofol. In: Clinical. Anesthesiology. 3 th edition, New York: Mc Graw-Hill, 2002: 173-174.
Reves JG, Glass P, Lubarsky DA, et al: Intravenous nonopioid anesthetics, in Miller RD (ed): Miller’s Anesthesia, 6th ed. Philadelphia: Elsevier Churchill Livingstone, 2005:317-378
Radovanović D, P. M. Ketamine: the past 30 years and its future. Medicinski Pregled 2002; 56(9-10):439-45.
Anästhesie. 5. Auflage. München - Wien - Baltimore: Urban und Schwarzenberg 1995: 221-45
Schmid, R. L., A. N. Sandler, et al. Use and efficacy of low-dose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes. Pain 1999; 82(2): 111-25
Lerch C, Park BGR. Sedation and analgesia. British Medical Bulletin 1995;55(1):76–95
Morgan GE, Mikhail MS, Murray MJ. Klinik Anesteziyoloji (Çev. M.Tulunay), Ağrı Tedavisi, Ankara, Güneş Tıp Kitapevleri 2008;s.286
Cullis B, Macnaughton P. Sedation and neuromuscular paralysis in the ICU. Anaesthesia & Intensive Care Medicine 2006; 8(1): 1-12
Twersky RS, J. B. Hemodynamics and emergence profile of remifentanil versus fentanyl prospectively compared in a large population of surgical patients. Journal of Clinical Anaesthesia, 2006; 13: 407–416.
Guldbrand P, B. L. Survey of routines for sedation of patients on controlled ventilation in Nordic intensive care units. . Acta Anaesthesiologica Scandinavica 2004; 48: 944-950
Mantz, J, Dexmedetomidine. Drugs Today (Bare), USA, 1999; 35:3, 151-7
Gertler R, Brown C, Mitchell DH, Silvius EN. Dexmedetomidine: a novel sedative - analgesic agent. BUMC Proceedings 2001; 14: 13 – 27
Aantaa, R., Kallio, A., & Virtanen, R.E. (1993). Dexmedetomidine, a novel alpha 2-adrenergic agonist. A review of its pharmacodynamic characteristics. Drugs of The Future, 18, 49-56.
Bol CJ, Vogelaar JP, Mandema JW. Anesthetic profile of dexmedetomidine identified by stimulus-response and continuous measurements in rats. J Pharmacol Exp Ther, 1999; 291:1, 153-60.
Venn RM, Hell J, Grounds RM. Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. Crit Care. 2000; 4(5): 302-8.
Bhana N, Goa KL, McClellan KJ. Dexmedetomidine. Drugs. 2000, 59(2): 263-8.
Albert RK, S. A. Klinik Yoğun Bakım. İstanbul Medikal Yayıncılık. İstanbul. 2009: s. 51-59.
Rinaldi, S., Consales, G., & De Gaudio, A. R. (2006). Sedation monitoring in ICU. Current Anaesthesia & Critical Care, 17(5), 303-315.
Jacobi, J., Fraser, G. L., Coursin, D. B., Riker, R. R., Fontaine, D., Wittbrodt, E. T., ... & Lumb, P. D. (2002). Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Critical care medicine, 30(1), 119-141.
Carrasco, G. (2000). Instruments for monitoring intensive care unit sedation. Critical Care, 4(4), 1-9.
Ramsay, M. A. E., Savege, T. M., Simpson, B. R. J., & Goodwin, R. (1974). Controlled sedation with alphaxalone-alphadolone. Br med J, 2(5920), 656-659.
Sessler, C. N., Gosnell, M. S., Grap, M. J., Brophy, G. M., O'Neal, P. V., Keane, K. A., ... & Elswick, R. K. (2002). The Richmond Agitation–Sedation Scale: validity and reliability in adult intensive care unit patients. American journal of respiratory and critical care medicine, 166(10), 1338-1344.
Rosow C, Manberg PJ. Bispectral index monitoring. Anesth Clin North Am 1998;2: 89–107.
Mahla M, Black S, Cucchiara RF. Neurologic monitoring. In Miller RD, ed., Miller's Anesthesia. Philadelphia, PA: Elsevier, 2000: 1324–50.
Abke J, Nahm W, Stockmanns Get al. Detection of inadequate anesthesia by EEG power and bispectral analysis. Anesthesiology 1996; 85: (suppl 3A): A477.
Adams, C. D., Altshuler, J., Barlow, B. L., Dixit, D., Droege, C. A., Effendi, M. K., ... & Berger, K. (2020). Analgesia and Sedation Strategies in Mechanically Ventilated Adults with COVID‐19. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 40(12), 1180-1191.
Spinelli, E., Mauri, T., Beitler, J. R., Pesenti, A., & Brodie, D. (2020). Respiratory drive in the acute respiratory distress syndrome: pathophysiology, monitoring, and therapeutic interventions. Intensive care medicine, 46(4), 606-618.
Papazian, L., Aubron, C., Brochard, L., Chiche, J. D., Combes, A., Dreyfuss, D., ... & Faure, H. (2019). Formal guidelines: management of acute respiratory distress syndrome. Annals of intensive care, 9(1), 1-18.
Hanidziar, D., & Bittner, E. A. (2020). Sedation of mechanically ventilated COVID-19 patients: challenges and special considerations. Anesthesia and Analgesia.
Madhok, J., & Mihm, F. G. (2020). Rethinking sedation during prolonged mechanical ventilation for coronavirus disease 2019 respiratory failure. Anesthesia and Analgesia.
Kaafarani HMA, Moheb ME, Hwabejire. JO, et al. Gastrointestinal Complications in. Critically Ill Patients With COVID-19. Ann. Surg 2020; 272: e61–e62.
Cruces, P., Retamal, J., Hurtado, D. E., Erranz, B., Iturrieta, P., González, C., & Díaz, F. (2020). A physiological approach to understand the role of respiratory effort in the progression of lung injury in SARS-CoV-2 infection. Critical care, 24(1), 1-10.
Hirsch JS, Ng JH, Ross DW, et al: Acute kidney injury in patients hospitalized with COVID-19. Kidney Int 98(1):209-218.
Phipps, M. M., Barraza, L. H., LaSota, E. D., Sobieszczyk, M. E., Pereira, M. R., Zheng, E. X., ... & Verna, E. C. (2020). Acute liver injury in COVID‐19: prevalence and association with clinical outcomes in a large US cohort. Hepatology, 72(3), 807-817.
Patel, S. B., & Kress, J. P. (2012). Sedation and analgesia in the mechanically ventilated patient. American journal of respiratory and critical care medicine, 185(5), 486-497.
Barr, J., Fraser, G. L., Puntillo, K., Ely, E. W., Gélinas, C., Dasta, J. F., ... & Jaeschke, R. (2013). Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Critical care medicine, 41(1), 263-306.
Sanavia, E., Mencía, S., Lafever, S. N., Solana, M. J., Garcia, M., & López-Herce, J. (2019). Sedative and analgesic drug rotation protocol in critically ill children with prolonged sedation: evaluation of implementation and efficacy to reduce withdrawal syndrome. Pediatric Critical Care Medicine, 20(12), 1111-1117.
